Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Despite advances in treatment, the overall survival rate remains low because most patients are diagnosed at advanced stages of the disease. Early detection and accurate risk stratification are critical for improving clinical outcomes and reducing mortality.
Low-dose computed tomography (LDCT) is the authoritative early screening method recommended by guidelines. However, the majority of detected nodules are benign, creating substantial challenges in clinical decision-making, follow-up management, and healthcare resource utilization. Therefore, reliable biomarkers that can assist in differentiating malignant from benign nodules and identifying individuals at high risk of lung cancer are increasingly important.
Genrui offers autoantibodies diagnostic reagent and corresponding platform to help Lung Nodule Risk Assessment.
Lung cancer occurs when abnormal cells grow uncontrollably in the lungs. It is a serious disease and remains a major public health challenge worldwide due to its high incidence andmortality. It was the leading cause of cancer death, with an estimated 2.5 million cases and 1.8 million deaths.
Low-dose computed tomography (LDCT) is the authoritative early screening method recom-mended by guidelines.
However, Its limited specificity makes it difficult to accurately distinguish benign frommalignant nodules. The detection rate of pulmonary nodules by LDCT is approximately 20%,of which more than 90% are benign.
Precise risk stratification and standardized management of lung nodules have become a core component of lung cancer screening programs.
Early lung cancer screening helps detect abnormalities early and enables prompt treatment.
During tumorigenesis, abnormal proteins (tumor-associated antigens) may be expressed, triggering an immune response that leads to the production of specific autoantibodies.
These tumor-associated autoantibodies can reflect biological changes in tumor development and immune surveillance. Importantly, the invasive tendency of tumor biological activity reflected by tumor immune response signals, thereby indicating the possibility of tumor malignant transformation.
Genrui offers a Seven Lung Cancer-associated Autoantibodies Detection Kit and corresponding device - the Chemiluminescence Immunoassay Analyzer.
Feb.17, 2026
Live From Dubai: Genrui at WhxLabs 2026
Nov.25, 2025
Live From Düsseldorf: Genrui at Medica 2025
Aug.05, 2025
Live From Chicago: Genrui at ADLM 2025